Key result
Percutaneous transcatheter pulmonary and tricuspid valve-in-valve replacement was reported for the first time to treat bioprosthesis degeneration in a patient with carcinoid heart disease.
Why the study?
Surgical valve replacement is the most effective treatment for carcinoid heart disease, but reoperation for prosthetic valve failure carries high risk.
This case report demonstrates the initial feasibility of percutaneous transcatheter pulmonary and tricuspid valve-in-valve replacement for bioprosthesis degeneration in a patient with carcinoid heart disease.
Answers are grounded in this paper and cite their sources.
Initial case supports procedural feasibility in carcinoid heart disease; hypothesis-generating and should not yet change practice.
Surgical valve replacement is the most effective treatment for carcinoid heart disease; however, reoperation for prosthetic valve failure is burdened by high risk. We report the first described percutaneous transcatheter pulmonary and tricuspid valve-in-valve replacement for bioprosthesis degeneration for any reason in a patient with carcinoid heart disease. (Level of Difficulty: Advanced.)
No takes yet. Share an insight, caveat, or question.
Luthra et al. (2020) studied this question. Percutaneous transcatheter pulmonary and tricuspid valve-in-valve replacement was reported for the first time to treat bioprosthesis degeneration in a patient with carcinoid heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: